Cargando…

Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review

BACKGROUND: Antithrombotic drugs increase the risk of bleeding, especially in patients who need urgent surgery without an adequate wash-out period. This review aims to evaluate perioperative bleeding complications in patients on dual antiplatelet therapy (DAPT) or direct-acting oral anticoagulants (...

Descripción completa

Detalles Bibliográficos
Autores principales: Matejic-Spasic, Marijana, Hassan, Kambiz, Thielmann, Matthias, Geidel, Stephan, Storey, Robert F., Schmoeckel, Michael, Adamson, Harriet, Deliargyris, Efthymios N., Wendt, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442533/
https://www.ncbi.nlm.nih.gov/pubmed/36071758
http://dx.doi.org/10.21037/jtd-22-428
_version_ 1784782834775359488
author Matejic-Spasic, Marijana
Hassan, Kambiz
Thielmann, Matthias
Geidel, Stephan
Storey, Robert F.
Schmoeckel, Michael
Adamson, Harriet
Deliargyris, Efthymios N.
Wendt, Daniel
author_facet Matejic-Spasic, Marijana
Hassan, Kambiz
Thielmann, Matthias
Geidel, Stephan
Storey, Robert F.
Schmoeckel, Michael
Adamson, Harriet
Deliargyris, Efthymios N.
Wendt, Daniel
author_sort Matejic-Spasic, Marijana
collection PubMed
description BACKGROUND: Antithrombotic drugs increase the risk of bleeding, especially in patients who need urgent surgery without an adequate wash-out period. This review aims to evaluate perioperative bleeding complications in patients on dual antiplatelet therapy (DAPT) or direct-acting oral anticoagulants (DOACs) undergoing high-bleeding risk cardiovascular surgery and to present currently available potential solutions to mitigate antithrombotic therapy-related bleeding complications. METHODS: As a first step, we searched for relevant articles, over the last 10 years, in Medline (PubMed) and abstracted clinical information based on pre-defined criteria for bleeding complications. In the next step, an additional search evaluating potential solutions to mitigate bleeding complications was performed. The literature screening and selection process followed the principles derived from the PRISMA statement. RESULTS: From all reviewed studies, a total of 19 articles could be included evaluating the risk for bleeding in cardiac surgery related to DAPT or DOACs and 10 papers evaluating antithrombotic drug reversal or removal in the setting of cardiovascular surgery. Reported bleeding rates ranged between 18% and 41%. The variability of the reported data is remarkable. Idarucizumab is reported to provide optimal perioperative hemostasis in up to 93% of patients. It has been observed that andexanet alfa causes unresponsiveness to the anticoagulant effects of heparin. Antithrombotic removal by intraoperative hemoadsorption is found to be associated with a significant decrease in re-thoracotomy rate, overall procedure duration, administered transfusion volumes, chest-tube drainage, and length of hospitalization. DISCUSSION: Bleeding complications in patients treated with DAPT or DOACs in cardiac surgery are high. New costly reversal agents are available but have not been sufficiently tested in the cardio-surgical setting so far. Interestingly, bleeding-related complications seem to be effectively reduced by applying innovative intraoperative hemoadsorption techniques. Expected results from the ongoing trials should provide better insights concerning the efficacy and safety of several potential solutions. Currently, the variability of reports and the deficit of high-quality studies in this specific setting represent the major limitation for the unbiased conclusion of this review.
format Online
Article
Text
id pubmed-9442533
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-94425332022-09-06 Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review Matejic-Spasic, Marijana Hassan, Kambiz Thielmann, Matthias Geidel, Stephan Storey, Robert F. Schmoeckel, Michael Adamson, Harriet Deliargyris, Efthymios N. Wendt, Daniel J Thorac Dis Review Article BACKGROUND: Antithrombotic drugs increase the risk of bleeding, especially in patients who need urgent surgery without an adequate wash-out period. This review aims to evaluate perioperative bleeding complications in patients on dual antiplatelet therapy (DAPT) or direct-acting oral anticoagulants (DOACs) undergoing high-bleeding risk cardiovascular surgery and to present currently available potential solutions to mitigate antithrombotic therapy-related bleeding complications. METHODS: As a first step, we searched for relevant articles, over the last 10 years, in Medline (PubMed) and abstracted clinical information based on pre-defined criteria for bleeding complications. In the next step, an additional search evaluating potential solutions to mitigate bleeding complications was performed. The literature screening and selection process followed the principles derived from the PRISMA statement. RESULTS: From all reviewed studies, a total of 19 articles could be included evaluating the risk for bleeding in cardiac surgery related to DAPT or DOACs and 10 papers evaluating antithrombotic drug reversal or removal in the setting of cardiovascular surgery. Reported bleeding rates ranged between 18% and 41%. The variability of the reported data is remarkable. Idarucizumab is reported to provide optimal perioperative hemostasis in up to 93% of patients. It has been observed that andexanet alfa causes unresponsiveness to the anticoagulant effects of heparin. Antithrombotic removal by intraoperative hemoadsorption is found to be associated with a significant decrease in re-thoracotomy rate, overall procedure duration, administered transfusion volumes, chest-tube drainage, and length of hospitalization. DISCUSSION: Bleeding complications in patients treated with DAPT or DOACs in cardiac surgery are high. New costly reversal agents are available but have not been sufficiently tested in the cardio-surgical setting so far. Interestingly, bleeding-related complications seem to be effectively reduced by applying innovative intraoperative hemoadsorption techniques. Expected results from the ongoing trials should provide better insights concerning the efficacy and safety of several potential solutions. Currently, the variability of reports and the deficit of high-quality studies in this specific setting represent the major limitation for the unbiased conclusion of this review. AME Publishing Company 2022-08 /pmc/articles/PMC9442533/ /pubmed/36071758 http://dx.doi.org/10.21037/jtd-22-428 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Matejic-Spasic, Marijana
Hassan, Kambiz
Thielmann, Matthias
Geidel, Stephan
Storey, Robert F.
Schmoeckel, Michael
Adamson, Harriet
Deliargyris, Efthymios N.
Wendt, Daniel
Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review
title Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review
title_full Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review
title_fullStr Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review
title_full_unstemmed Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review
title_short Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review
title_sort management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442533/
https://www.ncbi.nlm.nih.gov/pubmed/36071758
http://dx.doi.org/10.21037/jtd-22-428
work_keys_str_mv AT matejicspasicmarijana managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT hassankambiz managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT thielmannmatthias managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT geidelstephan managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT storeyrobertf managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT schmoeckelmichael managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT adamsonharriet managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT deliargyrisefthymiosn managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview
AT wendtdaniel managementofperioperativebleedingriskinpatientsonantithromboticmedicationsundergoingcardiacsurgeryasystematicreview